New consumer research reveals that while 37% of shoppers are buying more frequently due to personalized recommendations, a significant pullback is expected next year
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
